Tuesday, March 20, 2018 5:00:35 PM
I believe that is a total misread of the company. From the earliest days until 2010 started, just a normal little biotech startup.
2010 started out as the dream year with much, much larger market cap as phase 3 was reaching a conclusion.
Phase 3 was done with an inferior filter and an inferior treatment plan and compounded further by allowing crossover. Those obstacles were huge. Hope completely died in 2013 as FDA wanted a redo from scratch.
Simpson imo was cautious, careful, and slow about starting a new phase 3, which was started in early 2016 I believe. The slow clinical progress and high cash burn was all to the bad. 2016 was a very bad year for market cap and led to convertible.
Or one can just say scam, if one is so pleased. If there is not another convertible then the story moves on, b/o, bankruptcy or very significant dilution but not likely 45,000 fold share increase ala convertible
2010 started out as the dream year with much, much larger market cap as phase 3 was reaching a conclusion.
Phase 3 was done with an inferior filter and an inferior treatment plan and compounded further by allowing crossover. Those obstacles were huge. Hope completely died in 2013 as FDA wanted a redo from scratch.
Simpson imo was cautious, careful, and slow about starting a new phase 3, which was started in early 2016 I believe. The slow clinical progress and high cash burn was all to the bad. 2016 was a very bad year for market cap and led to convertible.
Or one can just say scam, if one is so pleased. If there is not another convertible then the story moves on, b/o, bankruptcy or very significant dilution but not likely 45,000 fold share increase ala convertible
Recent DCTH News
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:06:06 PM
- Delcath Systems Reports Fourth Quarter and Full Year 2025 Results • Business Wire • 02/26/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:05 AM
- Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call • Business Wire • 02/12/2026 01:00:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 02/10/2026 07:41:34 PM
- Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference • Business Wire • 01/27/2026 01:05:00 PM
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/21/2026 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 09:41:41 PM
- Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results • Business Wire • 01/09/2026 01:05:00 PM
- Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma • Business Wire • 12/31/2025 01:00:00 PM
